首页> 外国专利> Use of digoxin immune Fab for the regulation of sodium/potassium ATPase activity in preeclamptic and eclamptic patients

Use of digoxin immune Fab for the regulation of sodium/potassium ATPase activity in preeclamptic and eclamptic patients

机译:地高辛免疫Fab在先兆子痫和子痫患者中调节钠/钾ATPase活性的用途

摘要

A method of regulating a preeclamptic/eclamptic patient's sodium/potassium ATPase activity includes the administration of digoxin immune Fab (ovine). Digoxin immune Fab (ovine) binds with the endogenous digitalis-like factor to prevent it from interfering with the functioning of the sodium/potassium ATPase, thereby allowing the patient's intracellular sodium and calcium to return to a more normal level. A method of controlling preeclampsia is also disclosed that includes the steps of providing a supply of digoxin immune Fab (ovine), calculating an appropriate dosage of the digoxin immune Fab (ovine) based on a patient's weight and using an assumed endogenous digitalis-like factor level, administering the appropriate dosage as an intravenous bolus, and repeating the administration of the appropriate dosage on a fixed schedule.
机译:调节先兆子痫/先兆子痫患者的钠/钾ATPase活性的方法包括给予地高辛免疫Fab(绵羊)。地高辛免疫Fab(绵羊)与内源性洋地黄样因子结合,以防止其干扰钠/钾ATPase的功能,从而使患者的细胞内钠和钙恢复至更正常的水平。还公开了一种控制先兆子痫的方法,该方法包括以下步骤:提供地高辛免疫Fab(绵羊)的供应,基于患者的体重并使用假定的内源性洋地黄样因子来计算适当的地高辛免疫Fab(绵羊)的剂量。水平,以静脉推注方式施用适当的剂量,并按照固定的时间表重复施用适当的剂量。

著录项

  • 公开/公告号AU2003254159B2

    专利类型

  • 公开/公告日2009-09-24

    原文格式PDF

  • 申请/专利权人 ADAIR CHARLES DAVID;

    申请/专利号AU20030254159

  • 发明设计人 CHARLES DAVID ADAIR;

    申请日2003-07-24

  • 分类号A61K39/395;A61P1/16;A61P7;A61P7/04;A61P7/10;A61P9;A61P9/12;A61P11;A61P13/02;A61P13/12;A61P15/06;A61P25;A61P27/02;A61P39;A61P43;C07K16/44;

  • 国家 AU

  • 入库时间 2022-08-21 19:22:44

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号